Dr. Stephen E. Smith, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Morehouse School of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,086
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Morehouse School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
FL license ME75617
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Stephen E Smith MD PA (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,086
- Services billed
- 3,967
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient complete exam of visual system | 1,190 | 802 |
| Imaging of retina | 660 | 594 |
| Established patient problem focused exam of visual system | 472 | 257 |
| Photography of the retina | 375 | 363 |
| Removal of cataract with insertion of prosthetic lens | 220 | 125 |
| New patient complete exam of visual system | 195 | 195 |
| Removal of recurring cataract in lens capsule using a laser | 190 | 115 |
| Exam of visual field with extended testing | 172 | 158 |
| Measurement of corneal curvature and depth of eye | 111 | 110 |
| Insertion of drug delivery implant into tear duct of eye | 109 | 61 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Fort Myers, FL | 383 |
| Prednisolone Acetate Other prescribers in Fort Myers, FL | 260 |
| Timolol Maleate Other prescribers in Fort Myers, FL | 203 |
| Lotemax Sm (loteprednol etabonate) | 193 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Fort Myers, FL | 177 |
| Brimonidine Tartrate Other prescribers in Fort Myers, FL | 144 |
| Restasis (cyclosporine) Other prescribers in Fort Myers, FL | 133 |
| Besivance (besifloxacin hcl) | 122 |
| Vyzulta (latanoprostene bunod) | 119 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Fort Myers, FL | 115 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 31 payments worth $982 in total to this clinician.
| Biotissue Holdings Inc. | $396 |
|---|---|
| Bausch & Lomb Americas Inc. | $153 |
| Alcon Vision LLC | $93.41 |
| Glaukos Corporation | $81.43 |
| Dompe US, Inc. | $76.20 |
| Mallinckrodt Hospital Products Inc. | $76.17 |
| Tarsus Pharmaceuticals, Inc. | $40.65 |
| AbbVie Inc. | $23.48 |
| Food and Beverage | $982 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $54,219 in research payments for these studies, mostly to the institutions running them.
- Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects …
Glaukos Corporation - A prospective, multicenter study of the glaukos istent infinite trabecular micro-bypass system model IS3 in subjects with mild to moderate primary open-angle glaucoma
Glaukos Corporation - Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
AbbVie Inc. · Completed · NCT03891446
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.